Navigation Links
Preclinical study finds drug helps against pancreatic cancer

October 23, 2013(BRONX, NY)An investigational drug that disrupts tumor blood vessels shows promise against a rare type of pancreatic cancer, scientists at Albert Einstein College of Medicine of Yeshiva University have found. Their results were presented October 20 during a poster session at an international cancer conference.

The drug Zybrestat selectively targets and collapses tumor blood vessels, depriving the tumor of oxygen and making its cells die. In experiments involving a mouse model of pancreatic neuroendocrine tumors, Einstein scientists found that infusing mice with Zybrestat three times per week for four weeks resulted in significant antitumor activity compared with control mice given a placebo.

The findings were presented in Boston at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer Therapeutics. Presenting for Einstein was ZiQiang Yuan, M.D., research assistant professor of surgery at Einstein. The senior author is Steven K. Libutti, M.D., professor of genetics at Einstein and professor and vice chair of surgery at Einstein and Montefiore Medical Center, the University Hospital and academic medical center for Einstein.

Pancreatic cancer is the fourth-leading cause of cancer death in the U.S. According to the National Cancer Institute, more than 45,000 Americans will be diagnosed with pancreatic cancer in 2013 and more than 38,000 will die of the disease. Exocrine pancreatic cancer, the more common and usually fatal type, begins in the ducts that carry pancreatic juices. The Einstein study involved endocrine pancreatic cancerthe much less common and more curable form of the disease that originates in pancreatic cells that make hormones (and that caused the death of Apple co-founder Steve Jobs).

All the mice in the study had insulinomasendocrine tumors that form in pancreatic cells that make insulin, the hormone that controls glucose levels in the blood. This type of tumor can make the pancreas over-secrete insulin. The Einstein researchers found that treating the mice with Zybrestat caused a significant and sustained decrease in circulating insulin and also significantly reduced tumor size.

Zybrestat has been evaluated in clinical trials involving patients with anaplastic thyroid cancer, a highly aggressive cancer for which there are no approved treatments. The drug is made by OXiGENE, Inc., a biotech company based in San Francisco, CA.

Dr. Libutti is also director of the Montefiore Einstein Center for Cancer Care and associate director, clinical services at the Albert Einstein Cancer Center. This research was supported in part by OXiGENE, Inc. through a sponsored research agreement with Einstein. The authors report no conflicts of interest.


Contact: Deirdre Branley
Albert Einstein College of Medicine

Related medicine news :

1. Preclinical data support ongoing clinical trials testing IDO inhibitors as a treatment for cancer
2. Genetically-engineered preclinical models predict pharmacodynamic response
3. Preclinical study identifies master proto-oncogene that regulates ovarian cancer metastasis
4. Preclinical tests shows agent stops slippery proteins from binding, causing Ewing sarcoma
5. Mayo Clinic: Preclinical tests may lead to new approach to treat CNS lymphoma
6. Study Suggests Vaccine May Help Kids With Brain Cancer
7. Study reveals how cancer drug causes diabetic-like state
8. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
9. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. No Added Cancer Risk From Hip Replacement Materials: Study
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... of Toronto and the University of British Columbia suggested that laws requiring bicyclists to ... article explains that part of the reason for the controversial conclusion is that, while ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors has ... it. Surviving Mesothelioma has just posted the findings on the website. Click here ... the cases of 136 mesothelioma patients who were treated with chemotherapy followed by EPP ...
(Date:11/27/2015)... CA (PRWEB) , ... November 27, 2015 , ... Lizzie’s ... , The company is offering customers 10% off of their purchase of lice treatment ... treatment at full price. According to a company spokesperson. “Finding lice is a sure ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating community in ... (see Table 1-1 ). More than 3.7 billion people under the age of ... 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . , "The ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A simply ... Jones, is an interesting show that delves into an array of issues that are ... that could benefit from open dialogue, this show is changing the subjects consumers focus ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... Global Cell Surface Testing Market: Supplier ... to their offering.  --> ... of the  "2016 Future Horizons and ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 ... of the "Radioimmunoassay Market by Type ... Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application ... Forecast to 2020" report to their ... announced the addition of the "Radioimmunoassay ...
Breaking Medicine Technology: